Arcus Biosciences, Inc.
3928 Point Eden Way
Hayward
California
94545
United States
Tel: 510-694-6000
Website: http://www.arcusbio.com/
Email: jobs@arcusbio.com
About Arcus Biosciences, Inc.
Arcus was founded in 2015 with the vision of bringing together scientists, physicians, advisors, and other leaders with significant content-matter expertise to focus on developing highly-combinable, best-in-class cancer therapies. The complexity of the tumor microenvironment requires a deep scientific understanding to guide judicious combinations of therapeutic agents with potential synergistic activity and the ability to identify biomarkers to select patients most likely to achieve significant, durable responses to treatment. Since our inception, our focus has primarily been targeting well-understood biological pathways where the biology had not yet yielded high-quality medicines.
One of Arcus's early key competitive advantages was building a strong foundation of an industry-leading group of individuals who run our world-class discovery engine and development organization. We believe discovery is not a commodity and have invested in building a high-performing research organization. Through the efforts of our discovery and development teams, we were able to bring our first molecule in the clinic from concept to the clinical stage development in less than 21 months.
We have complemented our productive discovery organization with clinical and commercial leadership that has led multiple cancer immunotherapy programs from early-stage development though to successful global launches. As Arcus advances its product candidates through clinical studies, we work closely with the medical community, patients and caregivers to facilitate participation in our clinical trials enabling potential breakthrough medicines to reach patients faster.
Today, with four product candidates in the clinic across more than a dozen clinical studies in areas of high unmet need, we are well on our way to becoming a fully integrated biopharmaceutical company creating best-in-class cancer therapies.
Stock Symbol: RCUS
Stock Exchange: NYSE
89 articles with Arcus Biosciences, Inc.
-
Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer
1/15/2021
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data from the dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, the first small-molecule CD73 inhibitor to enter the clinic, in metastatic pancreatic cancer at the ASCO 2021 Virtual Gastrointestinal Cancers Symposium (ASCO GI).
-
Arcus Biosciences Announces New Employment Inducement Grants - Jan 12, 2021
1/12/2021
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 31,600 shares of the Company’s common stock at an exercise price per share of $30.83, which was the closing price on January 8, 2021.
-
Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer at ASCO-GI Symposium
1/11/2021
- Preliminary data from the first dose-escalation cohorts, reported in an abstract released today, demonstrate encouraging signs of clinical activity for AB680 in combination with zimberelimab (anti-PD-1 antibody) and chemotherapy - Additional data, as of a cut-off date of December 9, 2020, to be presented at ASCO-GI on January 15 th
-
Arcus Biosciences Appoints Biotech Industry Veteran, Andrew Perlman, M.D., Ph.D. and Gilead’s SVP of Research Biology, Michael Quigley, Ph.D. to Its Board of Directors
1/6/2021
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andrew Perlman, M.D., Ph.D. and Michael Quigley, Ph.D. have joined the Company’s Board of Directors. Dr. Perlman will also serve as a member of Arcus’s Nominating and Corporate Governance Committee. Drs. Perlman and Quigley both have outstanding track records of success
-
Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer
12/10/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and WuXi Biologics (2269.HK), a global company with leading open-access biologics technology platforms, today announced an expansion of their existing strategic relationship under which the parties will discover anti-CD39 antibodies using WuXi Bio’s proprietary technology
-
Arcus Biosciences Announces New Employment Inducement Grants - Dec 10, 2020
12/10/2020
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted twenty new employees options to purchase a total of 310,500 shares of the Company’s common stock at an exercise price per share of $29.93, which was the closing price on December 8, 2020.
-
Arcus Biosciences to Participate in the Evercore ISI 3rd Annual HealthCONx Virtual Conference
11/18/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, December 2, 2020 at 10:30 a.m. Eastern Time.
-
Arcus Biosciences Announces New Employment Inducement Grants - Nov 10, 2020
11/10/2020
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 343,000 shares of the Company’s common stock at an exercise price per share of $21.53, which was the closing price on November 9, 2020.
-
Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates
11/5/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results for the third quarter ended September 30, 2020 and provided corporate updates.
-
Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus’s Novel Anti-TIGIT Antibody, Plus Imfinzi® in Stage III NSCLC
10/29/2020
Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus’s Novel Anti-TIGIT Antibody, Plus Imfinzi ® in Stage III NSCLC - Collaboration Further Strengthens Arcus’s Position at the Forefront of the Anti-TIGIT Field and Leverages AstraZeneca’s Leadership in the Curative-Intent Stage III NSCLC Setting - Registrational Trial for Domvanalimab plus Imfinzi Expected to Begin in 2021 - Further Builds on the Arcus-Gilea
-
Arcus will pair its investigational anti-TIGIT antibody domvanalimab (AB154) with AstraZeneca’s Imfinzi (durvalumab), a checkpoint inhibitor, in a Phase III study with patients who have unresectable Stage III NSCLC.
-
Arcus Biosciences Announces New Employment Inducement Grants - Oct 08, 2020
10/8/2020
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted seventeen new employees options to purchase a total of 559,000 shares of the Company’s common stock at an exercise price per share of $19.20, which was the closing price on October 8, 2020.
-
Jennifer Jarrett Returns to Arcus Biosciences as Chief Operating Officer
10/1/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Jennifer Jarrett has rejoined Arcus as Chief Operating Officer with responsibility for Arcus’s commercial and general & administrative organizations, including finance and human resources.
-
Arcus Biosciences Announces New Employment Inducement Grants - Sep 10, 2020
9/10/2020
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 120,500 shares of the Company’s common stock at an exercise price per share of $20.71, which was the closing price on September 8, 2020.
-
Arcus Biosciences to Participate in Upcoming September 2020 Investor Conferences
8/27/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming virtual investor conferences:
-
Arcus Biosciences Announces New Employment Inducement Grants - Aug 11, 2020
8/11/2020
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted eleven new employees options to purchase a total of 135,900 shares of the Company’s common stock at an exercise price per share of $22.96, which was the closing price on August 10, 2020.
-
Arcus Biosciences Announces Second Quarter 2020 Financial Results and Corporate Updates
8/6/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results for the second quarter ended June 30, 2020 and provided corporate updates.
-
Arcus Biosciences Announces New Employment Inducement Grant
8/4/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, as previously disclosed in its Form 8-K filed with the Securities and Exchange Commission on July 7, 2020, the company made an inducement grant to Robert C. Goeltz II, the newly-appointed Chief Financial Officer of Arcus
-
Arcus Biosciences to Participate in Upcoming August Investor Conferences
7/28/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming virtual investor conferences
-
Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies
7/13/2020
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today the closing of their option and co-development and co-commercialization partnership agreement signed on May 27, 2020.